The market's overwhelming 91.5% implied probability for no Hantavirus vaccine available in 2026 reflects the extended timelines inherent in vaccine development for this rodent-borne virus, which causes sporadic hantavirus pulmonary syndrome with no licensed product currently authorized by regulatory bodies. Authoritative surveillance data from agencies tracking emerging pathogens show limited case volumes and transmission rates that do not prioritize accelerated funding or large-scale trials, leaving most candidates in preclinical or early-phase testing with standard multi-year requirements for safety, efficacy, and manufacturing validation. While advances in platform technologies offer potential shortcuts, model projections and historical patterns for similar orthohantaviruses indicate realistic barriers to 2026 rollout; any unexpected Phase 3 success or emergency authorization could alter trajectories, though such shifts remain low-probability events pending new data releases.
Експериментальне резюме, згенероване ШІ з посиланням на дані Polymarket. Це не торгова порада і не впливає на вирішення цього ринку. · ОновленоHantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
$92,922 Обс.
$92,922 Обс.
Dec 31, 2026
$92,922 Обс.
$92,922 Обс.
Dec 31, 2026
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.The market's overwhelming 91.5% implied probability for no Hantavirus vaccine available in 2026 reflects the extended timelines inherent in vaccine development for this rodent-borne virus, which causes sporadic hantavirus pulmonary syndrome with no licensed product currently authorized by regulatory bodies. Authoritative surveillance data from agencies tracking emerging pathogens show limited case volumes and transmission rates that do not prioritize accelerated funding or large-scale trials, leaving most candidates in preclinical or early-phase testing with standard multi-year requirements for safety, efficacy, and manufacturing validation. While advances in platform technologies offer potential shortcuts, model projections and historical patterns for similar orthohantaviruses indicate realistic barriers to 2026 rollout; any unexpected Phase 3 success or emergency authorization could alter trajectories, though such shifts remain low-probability events pending new data releases.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Ринок відкрито: May 4, 2026, 10:39 AM ET
Обсяг
$92,922Дата завершення
Dec 31, 2026Ринок відкрито
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.The market's overwhelming 91.5% implied probability for no Hantavirus vaccine available in 2026 reflects the extended timelines inherent in vaccine development for this rodent-borne virus, which causes sporadic hantavirus pulmonary syndrome with no licensed product currently authorized by regulatory bodies. Authoritative surveillance data from agencies tracking emerging pathogens show limited case volumes and transmission rates that do not prioritize accelerated funding or large-scale trials, leaving most candidates in preclinical or early-phase testing with standard multi-year requirements for safety, efficacy, and manufacturing validation. While advances in platform technologies offer potential shortcuts, model projections and historical patterns for similar orthohantaviruses indicate realistic barriers to 2026 rollout; any unexpected Phase 3 success or emergency authorization could alter trajectories, though such shifts remain low-probability events pending new data releases.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Обсяг
$92,922Дата завершення
Dec 31, 2026Ринок відкрито
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...The market's overwhelming 91.5% implied probability for no Hantavirus vaccine available in 2026 reflects the extended timelines inherent in vaccine development for this rodent-borne virus, which causes sporadic hantavirus pulmonary syndrome with no licensed product currently authorized by regulatory bodies. Authoritative surveillance data from agencies tracking emerging pathogens show limited case volumes and transmission rates that do not prioritize accelerated funding or large-scale trials, leaving most candidates in preclinical or early-phase testing with standard multi-year requirements for safety, efficacy, and manufacturing validation. While advances in platform technologies offer potential shortcuts, model projections and historical patterns for similar orthohantaviruses indicate realistic barriers to 2026 rollout; any unexpected Phase 3 success or emergency authorization could alter trajectories, though such shifts remain low-probability events pending new data releases.
Експериментальне резюме, згенероване ШІ з посиланням на дані Polymarket. Це не торгова порада і не впливає на вирішення цього ринку. · Оновлено
Обережно з зовнішніми посиланнями.
Обережно з зовнішніми посиланнями.
Часті запитання